advertisement
Abstract #11416 Published in IGR 6-3
Switching to latanoprost monotherapy for 24 weeks in glaucoma patients
Takahashi I; Tanaka MEuropean Journal of Ophthalmology 2004; 14: 401-406
PURPOSE. To investigate the intraocular pressure lowering effect in glaucoma patients switched to latanoprost therapy from isopropyl unoprostone given as monotherapy or in combination with a β-blocker. METHODS. Patients with primary open angle glaucoma or normal tension glaucoma treated with 0.12% isopropyl unoprostone as monotherapy or in combination with a β-blocker were eligible for this single-center clinical study. Of the 51 patients (51 eyes) enrolled, 18 were men and 33 were women aged 62.1 ± 12.3 years (mean ± SD). Twenty-two patients had primary open angle glaucoma, and 29 patients had normal tension glaucoma. Intraocular pressure was measured twice within 3 months prior to the switch, and the mean value was taken as the baseline. The patients were then switched to latanoprost (0.005%) monotherapy (once-daily administration), and changes in intraocular pressure were monitored. One physician measured intraocular pressure after 4, 8, 16, and 24 weeks of administration in this 24-week study. RESULTS. The mean intraocular pressures were 16.0 ± 2.4 mmHg at baseline, 13.7 ± 2.3 mmHg after 4 weeks, 13.1 ± 2.1 mmHg after 8 weeks, 13.6 ± 2.0 mmHg after 16 weeks, and 13.3 ± 2.4 mmHg after 24 weeks. A significant decrease in intraocular pressure was noted at all time points in both groups (paired t-test, p < 0.0001), and the intraocular pressure lowering effect persisted through week 24 of administration (analysis of variance, p < 0.0001). CONCLUSIONS. Switching to latanoprost monotherapy elicits further reduction in intraocular pressure in patients with primary open angle glaucoma or normal tension glaucoma.
Dr. I. Takahashi, Department of Ophthalmology, Juntendo Urayasu Hospital, 2-1-1, Tomioka, Urayasu-shi, Chiba 279-0021, Japan
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
